Ipamorelin

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue first characterized in 1998 by Raun and colleagues in a landmark study published in the European Journal of Endocrinology (PMID 9849822). That paper gave ipamorelin the distinction of being described as the first selective growth hormone secretagogue, meaning it potently stimulates growth hormone release while producing minimal off-target hormonal effects — a key advance over its predecessors such as GHRP-6 and GHRP-2, which also elevated cortisol and prolactin. With a molecular weight of 711.85 Da and the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, the compound is relatively small and structurally stable compared to many peptide hormones.

Researchers have studied ipamorelin primarily because of its clean hormonal profile. Earlier growth hormone secretagogues produced meaningful spikes in adrenocorticotropic hormone (ACTH) and cortisol, limiting their therapeutic appeal. Ipamorelin's selectivity opened a new line of inquiry into whether pulsatile growth hormone release could be stimulated safely and reproducibly, with potential applications spanning musculoskeletal repair, body composition management, and nitrogen balance in catabolic states.

A 1999 study in Growth Hormone and IGF Research (PMID 10373343) demonstrated that ipamorelin induces longitudinal bone growth in rats, adding skeletal health to its early research portfolio. Interest later expanded to gastrointestinal and oncology-adjacent applications: a 2024 study in Physiology and Behavior (PMID 39043357) found that ipamorelin and the related compound anamorelin attenuated cisplatin-induced weight loss in ferrets, pointing toward potential utility in managing chemotherapy-related cachexia.

Orthopaedic and sports medicine researchers have taken notice as well. Two 2026 review articles — one in the Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews (PMID 41490200) and another in the American Journal of Sports Medicine (PMID 41476424) — include ipamorelin among peptide therapies being evaluated for tissue repair and recovery. Despite this broadening interest, ipamorelin remains in preclinical and investigational territory, with no approved human indication, and it has appeared in analyses of black market sports performance products (PMID 29864719), underscoring the gap between research context and real-world misuse.

Ipamorelin acts as an agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), a G-protein-coupled receptor expressed in the pituitary gland, hypothalamus, and various peripheral tissues. GHS-R1a is the endogenous receptor for ghrelin, a gut-derived hunger hormone, but ipamorelin binds this receptor independently of ghrelin and does not require ghrelin to be present for its activity.

Upon binding GHS-R1a on somatotroph cells in the anterior pituitary, ipamorelin activates the Gq/11 signaling cascade. This triggers phospholipase C (PLC), which cleaves phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 raises intracellular calcium, and DAG activates protein kinase C (PKC). Together, these signals stimulate the exocytosis of stored growth hormone. The result is a sharp, pulsatile release of growth hormone that mimics the body's natural secretory pattern.

What distinguishes ipamorelin from earlier growth hormone-releasing peptides is its receptor selectivity. The 1998 European Journal of Endocrinology study (PMID 9849822) demonstrated that, unlike GHRP-6, ipamorelin does not significantly stimulate ACTH or cortisol release at doses that produce maximal growth hormone output. This selectivity is attributed to its pentapeptide structure and the specific orientation of its non-natural amino acids — D-2-naphthylalanine (D-2-Nal) and D-phenylalanine — which appear to favor pituitary GHS-R1a engagement over receptors in the adrenal axis.

Elevated growth hormone subsequently stimulates hepatic production of insulin-like growth factor-1 (IGF-1), which mediates many of the downstream anabolic and growth-promoting effects observed in animal models, including increased bone density and lean mass. A 2001 study in Biochemical and Biophysical Research Communications (PMID 11162489) reported GH-independent effects on adiposity when GHS-R1a agonists were used chronically, suggesting direct peripheral receptor effects beyond pituitary stimulation. Ipamorelin may also interact with the ghrelin signaling axis in the gastrointestinal tract, which partly explains findings in models of nociception and chemotherapy-induced weight loss.

The foundational research on ipamorelin begins with the 1998 paper by Raun et al. in the European Journal of Endocrinology (PMID 9849822), which characterized ipamorelin as the first selective growth hormone secretagogue. Working in rat and swine models, the investigators showed that ipamorelin produced robust, dose-dependent growth hormone release without the cortisol and prolactin elevations seen with GHRP-2 and GHRP-6. This selectivity became the defining feature that drove subsequent research interest.

Building on that foundation, a 1999 study in Growth Hormone and IGF Research (PMID 10373343) showed that ipamorelin promotes longitudinal bone growth in rats, with treated animals showing increased body weight gain and tibial bone growth compared to controls. This finding established a basis for musculoskeletal research with the compound. Separately, a 2009 study in the same journal (PMID 19231263) examined growth hormone and growth hormone secretagogue effects on nitrogen balance and urea synthesis in steroid-treated rats. That work found that ipamorelin improved nitrogen retention in a catabolic model, consistent with an anabolic role.

A 2001 study in Biochemical and Biophysical Research Communications (PMID 11162489) introduced a complicating nuance: chronic administration of GHS-R1a agonists — including ipamorelin — increased adiposity in rat models independent of growth hormone levels. This suggested that GHS-R1a stimulation in peripheral tissues could promote fat accumulation, a finding that tempers straightforward optimism about body composition benefits.

More recent work has expanded the research context. A 2020 study in the Journal of Experimental Pharmacology (PMID 32801950) explored ghrelin mimetics, including ipamorelin, in models of visceral and somatic pain, finding attenuation of nociceptive responses. A 2024 study in Physiology and Behavior (PMID 39043357) tested ipamorelin alongside anamorelin in ferrets undergoing cisplatin treatment and found that both compounds reduced chemotherapy-induced weight loss, with anamorelin additionally showing anti-emetic effects via a central mechanism.

In the sports and orthopedics literature, a 2020 review in Translational Andrology and Urology (PMID 32257855) discussed GH secretagogues — including ipamorelin — as adjuncts in managing body composition in hypogonadal males. Two 2026 reviews in orthopedic journals (PMID 41490200, PMID 41476424) include ipamorelin among injectable peptide therapies being studied for musculoskeletal applications. Critically, all clinical discussions remain at the review level; no completed phase II or III human trial has published primary outcome data specifically for ipamorelin.

No completed human trial has established a dose for ipamorelin. Any specific figures circulating online are unverified. Published animal studies used a range of doses to characterize hormonal responses, but these cannot be directly extrapolated to humans.

The safety profile of ipamorelin in humans has not been systematically established through peer-reviewed clinical trials. The available evidence comes primarily from animal studies and the 1998 characterization work, which identified receptor selectivity as a key safety advantage over earlier peptides in that class.

In animal models, the most notable safety observation is selectivity: the 1998 European Journal of Endocrinology study (PMID 9849822) showed that ipamorelin did not significantly increase cortisol, ACTH, or prolactin at doses producing maximal growth hormone release in rats and pigs. This profile contrasts with GHRP-6 and GHRP-2, where cortisol and prolactin rises were consistent findings and raised concerns about long-term adrenal and reproductive effects.

However, the 2001 Biochemical and Biophysical Research Communications study (PMID 11162489) raised a concern about chronic GHS-R1a agonism: prolonged administration in rats increased adiposity independent of growth hormone levels, suggesting that peripheral ghrelin receptor activation may promote fat deposition. This is a meaningful finding because it indicates that longer-term use could have metabolic consequences not immediately apparent from short-term growth hormone measurements.

Because ipamorelin stimulates growth hormone and subsequently IGF-1, theoretical concerns include potential promotion of existing neoplastic tissue, fluid retention, and carpal tunnel-like symptoms — effects seen with exogenous growth hormone administration. These concerns are theoretical in the context of ipamorelin specifically, as no long-term oncological safety data exist for this compound.

The appearance of ipamorelin in black market product analyses (PMID 29864719) highlights a practical safety concern: products sold outside regulated channels often contain incorrect doses, contaminants, or entirely different compounds. This means real-world safety incidents may not reflect what would occur under controlled research conditions. Anyone encountering this compound outside a clinical research setting faces unknown purity and dosing risks. The honest summary is that human long-term safety data do not exist, and caution is appropriate.

Ipamorelin remains an investigational compound with no approved therapeutic indication in any major regulatory jurisdiction as of 2025. The bulk of published primary research originates from animal studies conducted between 1998 and the mid-2000s, with the selective GHS-R1a agonism profile established in that period. More recent work has been largely preclinical, exploring GI motility, pain modulation, and chemotherapy-related cachexia in animal models.

Orthopaedic and sports medicine literature is beginning to incorporate ipamorelin into broader reviews of peptide therapies for musculoskeletal repair, as reflected in the 2026 journal reviews, but primary human trial data remain absent from the peer-reviewed literature. Interest in GHS-R1a agonists for oncology-related cachexia continues, though anamorelin — a related compound — has advanced further in clinical development, including regulatory approval in Japan. Ipamorelin trails anamorelin in clinical translation. The principal gaps are controlled human pharmacokinetic data, dose-finding studies, and long-term safety surveillance.